Company / R&D Expense
Anixa Biosciences Inc R&D Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$6.4M
FY2024
5-year range
$5.5M / $6.8M
FY2020-FY2024
Trend
-4.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 8 years, ranging from $711,391 in FY2016 to $7M in FY2019.
Based on SEC 10-K filings.
$6M in FY2024 with a 5-year CAGR of -1.3%.
Improved from $6M to $6M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -1.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.3%, indicating a declining trend.
- In FY2024, r&d expense decreased 4.6% year-over-year.
- Peak r&d expense was recorded in FY2019.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.4M | -4.6% |
| FY2023 | $6.7M | +8.3% |
| FY2022 | $6.2M | +13.1% |
| FY2020 | $5.5M | -19.7% |
| FY2019 | $6.8M | +326.5% |
| FY2018 | $1.6M | +2.6% |
| FY2017 | $1.6M | +118.8% |
| FY2016 | $711.4K | - |
| FY2015 | - | - |
| FY2014 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026